Two homologous sequences of HBV specific CRISPR/Cas9 systems were constructed.
The pCas9-2 produces better anti-HBV effects of in vitro and in vivo model.
The designed CRISPR/Cas9 system can provide a potential strategy for curing chronic HBV infection.